Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia

Overview

Journal Mov Disord Clin Pract

Publisher Wiley

Specialty Neurology

Date 2022 May 18

PMID 35582313

Authors

Judith A Boel

Rob M A de Bie

Ben A Schmand

John C Dalrymple-Alford

Connie Marras

Charles H Adler

Jennifer G Goldman

Alexander I Troster

David J Burn

Irene Litvan

Gert J Geurtsen

Affiliations

Soon will be listed here.

Abstract

Background: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.

Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.

Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, = 0.001; HR = 4.14, = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II.

Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.

Citing Articles

α-Synuclein Oligomers in Skin Biopsies Predict the Worsening of Cognitive Functions in Parkinson's Disease: A Single-Center Longitudinal Cohort Study.

Contaldi E, Basellini M, Mazzetti S, Calogero A, Colombo A, Cereda V Int J Mol Sci. 2024; 25(22).

PMID: 39596242 PMC: 11594322. DOI: 10.3390/ijms252212176.

German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions.

Kalbe E, Folkerts A, Witt K, Buhmann C, Liepelt-Scarfone I J Neurol. 2024; 271(11):7330-7357.

PMID: 39120709 PMC: 11561078. DOI: 10.1007/s00415-024-12503-0.

Social Cognition and Mild Cognitive Impairment in Mid-Stage Parkinson's Disease.

Fernandez-Fernandez R, Lahera G, Fernandez-Rodriguez B, Guida P, Trompeta C, Mata-Marin D Behav Sci (Basel). 2024; 14(2).

PMID: 38392454 PMC: 10885927. DOI: 10.3390/bs14020101.

Diagnostic value of plasma SIRT1 levels and whole-brain gray matter volume in Parkinson's disease patients with cognitive impairment.

Li X, Yang D, Ma J, Wei W, Zheng J, Fan Y Neurol Sci. 2023; 45(1):47-54.

PMID: 37718350 PMC: 10761499. DOI: 10.1007/s10072-023-07071-6.

Deep brain stimulation of globus pallidus internus and subthalamic nucleus in Parkinson's disease: a multicenter, retrospective study of efficacy and safety.

Mainardi M, Ciprietti D, Pilleri M, Bonato G, Weis L, Cianci V Neurol Sci. 2023; 45(1):177-185.

PMID: 37555874 PMC: 10761504. DOI: 10.1007/s10072-023-06999-z.

References

Skorvanek M, Goldman J, Jahanshahi M, Marras C, Rektorova I, Schmand B . Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2017; 33(2):208-218. DOI: 10.1002/mds.27233. View

Muslimovic D, Post B, Speelman J, Schmand B . Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005; 65(8):1239-45. DOI: 10.1212/01.wnl.0000180516.69442.95. View

Galtier I, Nieto A, Lorenzo J, Barroso J . Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia. J Clin Exp Neuropsychol. 2015; 38(1):40-50. DOI: 10.1080/13803395.2015.1087465. View

Marras C, Armstrong M, Meaney C, Fox S, Rothberg B, Reginold W . Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord. 2013; 28(5):626-33. PMC: 4524474. DOI: 10.1002/mds.25426. View

Geurtsen G, Hoogland J, Goldman J, Schmand B, Troster A, Burn D . Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis. 2013; 4(2):131-7. PMC: 4380013. DOI: 10.3233/JPD-130304. View

Hoops S, Nazem S, Siderowf A, Duda J, Xie S, Stern M . Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009; 73(21):1738-45. PMC: 2788810. DOI: 10.1212/WNL.0b013e3181c34b47. View

van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda J, Rick J . Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord. 2014; 29(14):1809-15. PMC: 4371590. DOI: 10.1002/mds.26062. View

Goetz C, Tilley B, Shaftman S, Stebbins G, Fahn S, Martinez-Martin P . Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15):2129-70. DOI: 10.1002/mds.22340. View

Hoogland J, Boel J, de Bie R, Schmand B, Geskus R, Dalrymple-Alford J . Risk of Parkinson's disease dementia related to level I MDS PD-MCI. Mov Disord. 2019; 34(3):430-435. DOI: 10.1002/mds.27617. View

10.

Dalrymple-Alford J, Livingston L, MacAskill M, Graham C, Melzer T, Porter R . Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord. 2011; 26(4):629-36. DOI: 10.1002/mds.23592. View

11.

Litvan I, Goldman J, Troster A, Schmand B, Weintraub D, Petersen R . Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012; 27(3):349-56. PMC: 3641655. DOI: 10.1002/mds.24893. View

12.

Beach T, Adler C, Sue L, Serrano G, Shill H, Walker D . Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology. 2015; 35(4):354-89. PMC: 4593391. DOI: 10.1111/neup.12189. View

13.

Litvan I, Aarsland D, Adler C, Goldman J, Kulisevsky J, Mollenhauer B . MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011; 26(10):1814-24. PMC: 3181006. DOI: 10.1002/mds.23823. View

14.

Hoogland J, Boel J, de Bie R, Geskus R, Schmand B, Dalrymple-Alford J . Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Mov Disord. 2017; 32(7):1056-1065. DOI: 10.1002/mds.27002. View